title: Amikacin alters auditory brainstem conduction time in newborns.
abstract: The purpose of this paper was to describe whether there are some relationships between amikacin serum levels and central conduction time in brainstem auditory evoked potentials (BAEP) within therapeutic range levels in newborns as index of drug toxicity in brainstem auditory centers in neonatally exposed infants. We performed a cross-sectional study to compare BAEP from 35 infants under amikacin administration and 24 control infants; both examinations were blinded to investigators. Bivariate and partial correlations were calculated between amikacin and BAEP measurements in treated infants. Amikacin determinations were within therapeutic levels. No clinical alterations in BAEP were found and no differences between amikacin-treated and control infants were found. Significant positive Pearson correlation between latency of I-III interwaves interval and amikacin Cmin serum levels was found and was present when calculations were controlled by partial correlations for gestational age at birth and Apgar score at 5 min. The findings suggest that increased amikacin levels in newborns are related to increased latencies in I-III interwave interval in infants, which may be an early index of brainstem effects of subclinical neurotoxicity of amikacin.
authors.affiliation: Department of Neurology, National Institute of Perinatology, Department of Neurological Rehabilitation, Metropolitan University at Xochimilco, Mexico. drdeaf@starmedia.com
authors.forename: Adrián
authors.initials: A
authors.lastname: Poblano
authors.forename: Aurora
authors.initials: A
authors.lastname: Belmont
authors.forename: Jesús
authors.initials: J
authors.lastname: Sosa
authors.forename: Jorge
authors.initials: J
authors.lastname: Ibarra
authors.forename: Ana María
authors.initials: AM
authors.lastname: Vargas
authors.forename: Gloria
authors.initials: G
authors.lastname: Limón
authors.forename: Carlos
authors.initials: C
authors.lastname: Martínez
mesh_terms: D000583:Amikacin / Q000009:adverse effects* / Q000097:blood; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000097:blood; D016057:Evoked Potentials, Auditory, Brain Stem / Q000187:drug effects*; D005260:Female; D005865:Gestational Age; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D015931:Intensive Care, Neonatal; D008297:Male
chemical_list: D000900:Anti-Bacterial Agents; D000583:Amikacin